ReiThera: GRAd-COV2
Vaccine Type: Non Replicating Viral Vector
Vaccine Trial & Approval Tracker
-
Phase 1
-
Phase 2
-
Phase 3
-
Approved
This vaccine has reached Phase 3 trials.
About Trial Phases
Phase 2:
2
Trials
-
EUCTR2020-005915-39
Argentina, Belgium, Brazil, Chile, Czechia, France, Germany, Indonesia, Italy, Malaysia, Poland, South Africa
-
NCT04791423
Italy
Phase 3:
2
Trials
-
EUCTR2020-005915-39
Argentina, Belgium, Brazil, Chile, Czechia, France, Germany, Indonesia, Italy, Malaysia, Poland, South Africa
-
NCT04791423
Italy
Approvals
This vaccine is not yet approved.
Registered Trials
-
EUCTR2020-005915-39
Phase 2/3
Argentina, Belgium, Brazil, Chile, Czechia, France, Germany, Indonesia, Italy, Malaysia, Poland, South Africa
Total Enrollment: 10,000
Official Trial Registration:
-
NCT04791423
Phase 2/3
Italy
Total Enrollment: 10,300
Official Trial Registration:
-
NCT04528641
Phase 1
Italy
Total Enrollment: 90
Official Trial Registration:
